Southern Copper Corp vs Twist Bioscience Corp — how do they compare? Southern Copper Corp trades at $206.35 (market cap $167.74B), while Twist Bioscience Corp trades at $161.09 (market cap $10.08B). The key difference: Southern Copper Corp is far larger — about 16.6× Twist Bioscience Corp's market cap, and Southern Copper Corp pays a 2.21% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Southern Copper Corp for 61 Days and Twist Bioscience Corp for 27 Days on average.
| SCCO | TWST | |
|---|---|---|
Market Cap | $167.74B | $10.08B |
Volume | 853,110 | 4,229,037 |
Sector | Basic Materials | Health |
52-Week High | $219.70 | $205.00 |
52-Week Low | $120.02 | $25.45 |
Typical Hold Time | 61 Days | 27 Days |
Enterprise Value | $169.03B | $10.01B |
Dividend Yield | 2.21% | — |
Signals from Pluang's Aura AI — not financial advice
Southern Copper (SCCO) trades at $200.57, down 1.81% on the day, with technical indicators showing a neutral bias. The company demonstrates strong fundamentals with revenue growth from $13.42B in 2025 to projected $15.8B in 2026 and net income margins expanding to 35.87%. Recent earnings have consistently beaten expectations, and the company maintains robust profitability metrics including 50.07% ROE. A stock split and dividend payment are scheduled for August 2026.
SCCO presents a mixed investment case with strong operational performance offset by premium valuations. The stock trades above analyst consensus target of $167.67, suggesting limited near-term upside. Key risks include copper price volatility and competitive pressures, while growth catalysts include Mexican project pipeline development. Analyst sentiment remains divided with only 10.34% buy ratings.
TWST trades at $155.65, down 6.78% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $377M in 2025, but the company remains unprofitable with a net income margin of -31.66%. Recent news highlights its role in Eli Lilly's AI-driven drug discovery platform, boosting sentiment despite earnings misses.
The outlook is mixed: analyst consensus is bullish with a $145.20 price target, but high valuation multiples and persistent losses pose risks. Investment opportunity hinges on AI partnerships driving future profitability, while execution risks and cash burn require careful monitoring.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Southern Copper Corp is an integrated producer of copper and other minerals and operates the mining, smelting, and refining facilities in Peru and Mexico. Its production includes copper, molybdenum, zinc, and silver. The company operates through the following segments: Peruvian operations, Mexican open-pit operations, and Mexican underground mining operations. Southern Copper generates the majority of its revenue from the sale of copper and the rest from the sale of non-copper products, such as molybdenum, silver, zinc, lead, and gold. Its geographical segments are The Americas, Europe, and Asia.
Read more on SCCO →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →